Back to top

Analyst Blog

Zacks Equity Research

Loss at Optimer in 1Q

CBST

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Optimer Pharma’s first quarter 2012 net loss (excluding special items) of 73 cents per share compared unfavorably with the year-ago earnings of $1.04 and the Zacks Consensus loss Estimate of 38 cents per share. Lower revenues and higher costs hurt results during the first quarter of 2012.

Revenues in the first quarter of 2012 came in at $14.4 million as opposed to $69.3 million in the year-ago quarter. We note that revenues in the year-ago quarter were boosted by the receipt of $69.2 million as upfront milestone payment from Optimer’s partner Astellas Pharma regarding Optimer’s sole marketed drug Dificid/Dificlir.

We remind investors that Dificid was launched in the U.S. in July 2011 for treating patients suffering from clostridium difficile-associated diarrhea (CDAD)-the most common form of nosocomial, or hospital acquired, diarrhea. Net sales of the drug came in at $14.4 million in the first quarter of 2012, up 31% sequentially. Dificid was approved in the European Union (E.U.) under the trade name, Dificlir, in December 2011. Revenues were well short of the Zacks Consensus Estimate of $30 million.

We note that Optimer has an exclusive two-year agreement with Cubist Pharmaceuticals (CBST - Analyst Report) (through July 2013) to co-promote Dificid in the U.S. for the treatment of CDAD.

Both selling, general and administrative (SG&A) expenses (up 116%) and research & development (R&D) expenses (up 32%) were on the upswing during the reported quarter. The massive increase in SG&A expenses was primarily attributable to the costs incurred by Optimer towards the marketing of Dificid. The increase in R&D expenses was attributable to higher publication and other expenses pertaining to the Dificid’s marketing.

Our Recommendation

Currently, we have a Neutral stance on Optimer  in the long run. The company carries a Zacks #2 Rank (“Buy” rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%